Immuneering Corporation will present at the Oppenheimer Healthcare Conference on February 26, 2026, discussing its oncology pipeline and strategy.
Quiver AI Summary
Immuneering Corporation, a late-stage clinical oncology company, announced that its management team, including CEO Ben Zeskind and Chief Scientific Officer Brett Hall, will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference, held virtually on February 25-26, 2026. They will discuss the company's pipeline, platform, and business strategy, with a live presentation scheduled for February 26 at 10:00 am ET. Immuneering focuses on developing innovative cancer treatments, specifically their lead candidate, atebimetinib, an oral Deep Cyclic Inhibitor of MEK, which aims to improve patient outcomes in MAPK pathway-driven tumors like pancreatic cancer. A Phase 3 trial for atebimetinib is set to begin in mid-2026. Investors and media can find more information on their website.
Potential Positives
- Immuneering Corporation will present at a significant investor conference, showcasing its pipeline and business strategy to potential investors.
- The company is developing an innovative category of cancer treatments, Deep Cyclic Inhibitors, which could position it favorably in the oncology market.
- The lead product candidate, atebimetinib, is set to enter a Phase 3 trial for first-line pancreatic cancer, indicating progress in clinical development.
Potential Negatives
- Management's presentation schedule may indicate a lack of immediate advancements or results in clinical trials, raising concerns among investors about the company's current progress.
- The mention of an upcoming Phase 3 trial without previously reported results from earlier phases could imply uncertainty regarding the efficacy and safety of their lead product, atebimetinib.
- The reference to only early-stage programs in the pipeline may highlight a potential lack of diversity and maturity in the company's product development efforts.
FAQ
What is the date of Immuneering's presentation at the Oppenheimer conference?
Immuneering will present on February 26, 2026, at 10:00 am ET.
Who will represent Immuneering at the conference?
Ben Zeskind, CEO, and Brett Hall, CSO, will represent Immuneering at the conference.
How can I access the Immuneering conference presentation?
The presentation will be webcast live and archived on Immuneering's Investor Relations section of their website.
What is Immuneering's lead product candidate?
Immuneering's lead product candidate is atebimetinib, a Deep Cyclic Inhibitor designed for cancer treatment.
What are Deep Cyclic Inhibitors?
Deep Cyclic Inhibitors are a new category of cancer medicines being developed by Immuneering to improve treatment outcomes.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$IMRX Insider Trading Activity
$IMRX insiders have traded $IMRX stock on the open market 11 times in the past 6 months. Of those trades, 11 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $IMRX stock by insiders over the last 6 months:
- PETER FEINBERG has made 4 purchases buying 40,000 shares for an estimated $225,559 and 0 sales.
- THOMAS J. SCHALL purchased 21,645 shares for an estimated $101,041
- HAROLD EUGENE BRAKEWOOD (Chief Business Officer) purchased 5,250 shares for an estimated $24,990
- LEAH R NEUFELD (CHIEF PEOPLE OFFICER) has made 2 purchases buying 3,426 shares for an estimated $16,009 and 0 sales.
- BRETT MATTHEW HALL (CHIEF SCIENTIFIC OFFICER) purchased 2,298 shares for an estimated $10,501
- MICHAEL BOOKMAN (CHIEF LEGAL OFFICER, SECRETARY) purchased 1,020 shares for an estimated $6,966
- MALLORY MORALES (Chief Accounting Officer) purchased 300 shares for an estimated $1,917
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$IMRX Hedge Fund Activity
We have seen 56 institutional investors add shares of $IMRX stock to their portfolio, and 27 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- EMPERY ASSET MANAGEMENT, LP added 2,674,950 shares (+inf%) to their portfolio in Q4 2025, for an estimated $17,601,171
- STATE STREET CORP added 2,229,374 shares (+1289.7%) to their portfolio in Q4 2025, for an estimated $14,669,280
- EXODUSPOINT CAPITAL MANAGEMENT, LP removed 1,516,833 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $9,980,761
- LOGOS GLOBAL MANAGEMENT LP removed 950,000 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $6,251,000
- FMR LLC added 898,443 shares (+10.2%) to their portfolio in Q4 2025, for an estimated $5,911,754
- CITADEL ADVISORS LLC removed 852,685 shares (-90.4%) from their portfolio in Q4 2025, for an estimated $5,610,667
- BLACKROCK, INC. added 770,521 shares (+113.1%) to their portfolio in Q4 2025, for an estimated $5,070,028
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$IMRX Analyst Ratings
Wall Street analysts have issued reports on $IMRX in the last several months. We have seen 5 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Chardan Capital issued a "Buy" rating on 11/13/2025
- Leerink Partners issued a "Outperform" rating on 10/31/2025
- HC Wainwright & Co. issued a "Buy" rating on 09/30/2025
- Oppenheimer issued a "Outperform" rating on 09/25/2025
- Needham issued a "Buy" rating on 09/15/2025
To track analyst ratings and price targets for $IMRX, check out Quiver Quantitative's $IMRX forecast page.
$IMRX Price Targets
Multiple analysts have issued price targets for $IMRX recently. We have seen 5 analysts offer price targets for $IMRX in the last 6 months, with a median target of $15.0.
Here are some recent targets:
- Geulah Livshits from Chardan Capital set a target price of $20.0 on 11/13/2025
- Andrew Berens from Leerink Partners set a target price of $15.0 on 10/31/2025
- Ami Fadia from HC Wainwright & Co. set a target price of $11.0 on 09/30/2025
- Jay Olson from Oppenheimer set a target price of $30.0 on 09/25/2025
- Ami Fadia from Needham set a target price of $11.0 on 09/15/2025
Full Release
NEW YORK, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today announced that management will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference, taking place virtually from February 25-26, 2026. Management, including Ben Zeskind, Chief Executive Officer, and Brett Hall, Chief Scientific Officer, will discuss the company’s pipeline, platform, and business strategy.
Format: Company Presentation and 1x1 Investor Meetings
Date/Time: Thursday, February 26, 2026, at 10:00 am ET
The presentation will be webcast live and archived in the Investor Relations section of Immuneering’s website at Events & Presentations | Immuneering Corporation .
About Immuneering Corporation
Immuneering is a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive. The Company is developing an entirely new category of cancer medicines, Deep Cyclic Inhibitors. Immuneering’s lead product candidate, atebimetinib, is an oral, once-daily Deep Cyclic Inhibitor of MEK, designed to improve durability and tolerability across many cancer indications, including MAPK pathway-driven tumors such as pancreatic cancer. Atebimetinib is currently planned to be evaluated in a Phase 3 trial in first-line pancreatic cancer, which is expected to begin dosing in mid-2026. The Company’s development pipeline also includes early-stage programs. For more information, please visit www.immuneering.com .
Media Contact:
Gina Nugent
[email protected]
Investor Contact:
Courtney Dugan
[email protected]
Laurence Watts
619-916-7620
[email protected]
